Trial Profile
A double-blind, randomized, placebo-controlled study of daily drospirenone/estradiol evaluating the pharmacokinetic/pharmacodynamic properties in postmenopausal women with moderate to severe vasomotor symptoms
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Dec 2015
Price :
$35
*
At a glance
- Drugs Estradiol/drospirenone (Primary)
- Indications Postmenopause
- Focus Pharmacodynamics; Pharmacokinetics
- 03 Dec 2015 New trial record